GC Cell has successfully hosted a Media Day event titled “K-Cell, Cure for Tomorrow” on Tuesday, held at Conrad Seoul in Yeouido and at its headquarters in Yongin.

The event consisted of a media briefing session followed by a guided tour of the company’s cell therapy manufacturing facilities. Key executives, including CEO James Park, Chief Administrative Officer Lee Chang-hwi, Cell Therapy Research Institute Director Won Seong-yong, Oncology Business Unit Head Kim Seung-hwan, Chief Business Office Chun Ji-won, and Chief Development Office Kang Jin-hee, presented the company’s current operations and strategic vision for the future.

During the opening session, CEO James Park shared the company’s ambition to drive global expansion in cell therapies.

“Until now, we have focused on strengthening our core capabilities and global competitiveness in the cell therapy sector,” Park said. “Moving forward, we aim to take K-cell therapies to the world, marking a new era of Korean cell therapy globally.”

The first session highlighted GC Cell’s R&D roadmap, key product updates, and strategies for global market expansion and open innovation.

The company introduced its proprietary fourth-generation CAR technology platform, aimed at developing new cell and gene therapies. Currently, GC Cell is advancing a diverse pipeline of therapies, including NK cell therapies and CAR-NK treatments, with ongoing clinical and research efforts.

A significant focus was placed on GC Cell’s flagship product, Immuncell-LC, a post-surgical adjuvant therapy for hepatocellular carcinoma (HCC).

The product has demonstrated promising clinical results, reducing cancer recurrence by 37 percent and mortality risk by 79 percent, attracting attention from major pharmaceutical companies and global oncology conferences.

Recently, GC Cell entered into a 16 billion won ($11.4 million) licensing agreement with Indonesia’s leading stem cell company, PT Bifarma Adiluhung, aiming to bring Immuncell-LC to market in Indonesia by 2025.

Company representatives shared plans to leverage the success in Indonesia to establish a foothold in other regions, including Russia, China, and the MENA (Middle East and North Africa) region over the next two years, with potential for future expansion into advanced markets.

The Media Day’s second part featured a tour of GC Cell’s Cell Center at the Yongin headquarters, showcasing its CDMO (contract development and manufacturing organization) facilities, Immuncell-LC production facilities, and its umbilical cord blood bank, Lifeline.